[go: up one dir, main page]

WO1996037214A3 - Compositions a base d'interleukine et de nucleosides de pyrimidine - Google Patents

Compositions a base d'interleukine et de nucleosides de pyrimidine Download PDF

Info

Publication number
WO1996037214A3
WO1996037214A3 PCT/EP1996/002088 EP9602088W WO9637214A3 WO 1996037214 A3 WO1996037214 A3 WO 1996037214A3 EP 9602088 W EP9602088 W EP 9602088W WO 9637214 A3 WO9637214 A3 WO 9637214A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukin
compositions
pyrimidine nucleosides
derivative
fluorouracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/002088
Other languages
English (en)
Other versions
WO1996037214A2 (fr
Inventor
Kazushige Mori
Yutaka Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to EP96917379A priority Critical patent/EP0828508A2/fr
Priority to AU59982/96A priority patent/AU5998296A/en
Priority to JP8535342A priority patent/JPH10506641A/ja
Priority to BR9608779A priority patent/BR9608779A/pt
Publication of WO1996037214A2 publication Critical patent/WO1996037214A2/fr
Publication of WO1996037214A3 publication Critical patent/WO1996037214A3/fr
Priority to MXPA/A/1997/008915A priority patent/MXPA97008915A/xx
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention porte sur une composition pharmaceutique synergique antitumorale, comprenant un volume efficace d'interleukine-12 et d'un dérivé de nucléoside de pyrimidine ainsi qu'un hydrate ou un solvate de celui-ci, converti en fluoro-uracil ou en un dérivé de ce dernier ainsi qu'un véhicule acceptable du point de vue pharmaceutique.
PCT/EP1996/002088 1995-05-26 1996-05-15 Compositions a base d'interleukine et de nucleosides de pyrimidine Ceased WO1996037214A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP96917379A EP0828508A2 (fr) 1995-05-26 1996-05-15 Compositions a base d'interleukine et de nucleosides de pyrimidine
AU59982/96A AU5998296A (en) 1995-05-26 1996-05-15 Compositions of interleukin and pyrimidine nucleosides
JP8535342A JPH10506641A (ja) 1995-05-26 1996-05-15 インターロイキン１２とピリミジンヌクレオシドの組成物
BR9608779A BR9608779A (pt) 1995-05-26 1996-05-15 Composições de interleucina e pirimidina nucleosideos
MXPA/A/1997/008915A MXPA97008915A (en) 1995-05-26 1997-11-19 Compositions of interleucine and nucleosides of pirimid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95108063 1995-05-26
EP95108063.9 1995-05-26

Publications (2)

Publication Number Publication Date
WO1996037214A2 WO1996037214A2 (fr) 1996-11-28
WO1996037214A3 true WO1996037214A3 (fr) 1997-01-09

Family

ID=8219298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002088 Ceased WO1996037214A2 (fr) 1995-05-26 1996-05-15 Compositions a base d'interleukine et de nucleosides de pyrimidine

Country Status (9)

Country Link
EP (1) EP0828508A2 (fr)
JP (1) JPH10506641A (fr)
CN (1) CN1184430A (fr)
AR (1) AR005417A1 (fr)
AU (1) AU5998296A (fr)
BR (1) BR9608779A (fr)
CA (1) CA2220837A1 (fr)
TR (1) TR199701435T1 (fr)
WO (1) WO1996037214A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882734B1 (fr) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag Dérivés de 5'-déoxy-cytidine
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMI Y ET AL: "Interleukin-12 (IL-12) enhances antitumor activity of chemotherapy and radiotherapy in murine models", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 36 (0). 01-03-1995. 480., XP000605926 *
JACOBSEN S.E.W.: "Il12, a direct stimulator and indirect inhibitor of haematopoiesis", RESEARCH IN IMMUNOLOGY, 01-01-1995, 146/7-8 (506-514), FRANCE, XP000607088 *

Also Published As

Publication number Publication date
BR9608779A (pt) 1999-07-06
AR005417A1 (es) 1999-06-23
MX9708915A (es) 1998-03-31
JPH10506641A (ja) 1998-06-30
AU5998296A (en) 1996-12-11
WO1996037214A2 (fr) 1996-11-28
CA2220837A1 (fr) 1996-11-28
TR199701435T1 (xx) 1998-03-21
CN1184430A (zh) 1998-06-10
EP0828508A2 (fr) 1998-03-18

Similar Documents

Publication Publication Date Title
IL118519A (en) Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives, their preparation and pharmaceutical compositions containing them
CA2211612A1 (fr) Nucleosides de [5-carboxamido ou 5-fluoro]-pyrimidine insaturee en 2',3' ou modifiee en 3'
HUP9802323A3 (en) Pyrimidine derivatives , process for producing them and pharmaceutical compositions containing them
EP2011499A3 (fr) Compositions de pyrrolo(2,3d)-pyrimidine et leur utilisation
WO2002100354A3 (fr) Analogues de pyrrolo[2,3-d]pyrimidine nucleoside
IL110992A0 (en) n-substituted 5'-deoxy adenosine derivatives and pharmaceutical compositions containing them
NZ227663A (en) Purine nucleoside analogues, pyrimidine derivatives and pharmaceutical compositions
AU7776891A (en) 5-benzyl barbiturate derivatives
NZ223272A (en) Avermectin derivatives and parasiticidal compositions
EP0821587A4 (fr) Compositions, trousses et procedes d'administration d'antilipemiques et medicaments contre l'agregation plaquettaire
IL92293A0 (en) 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives and pharmaceutical compositions containing them
AU4846697A (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
HUP9801394A3 (en) 6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them
IL98164A0 (en) Antiviral nucleoside derivatives,process for their preparation and pharmaceutical compositions containing them
NZ212673A (en) Avermectin and milbemycin derivatives and parasiticidal compositions
HUT61765A (en) Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient
IL95870A0 (en) Purine nucleoside derivatives,their preparation and pharmaceutical compositions containing them
AU3255097A (en) Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
HUP9900924A3 (en) Substituted 1 betha-d-arabinofuranosylcytosine derivatives and use of the same for producing pharmaceutical compositions having antitumor activity
AU3784089A (en) Avermectin and milbemycin derivatives from streptomyces avermitiosis ATCC 31267, 31271 and 31272
WO1996037214A3 (fr) Compositions a base d'interleukine et de nucleosides de pyrimidine
AU5829994A (en) Synergistic compositions containing an antiviral nucleoside analogue and an antiviral oligopeptide
IE891247L (en) Phosphonoalkylpurine derivatives
AU5883794A (en) Diazepin derivatives and antiviral compositions
AU8239891A (en) 5'-hydrogenphosphonates and 5'-methylphosphonates of sugar modified nucleosides, compositions and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194016.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BB BG BR CA CN CZ EE GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BB BG BR CA CN CZ EE GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2220837

Country of ref document: CA

Ref document number: 2220837

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996917379

Country of ref document: EP

Ref document number: PA/a/1997/008915

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 97/01435

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1996917379

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996917379

Country of ref document: EP